Drug class in one race
BCMA x CD3 drugs for Multiple Myeloma
11 tracked BCMA x CD3 drugs in the Multiple Myeloma race. The class explanation lives on the BCMA x CD3 page; the full indication pipeline across every mechanism is on the Multiple Myeloma page.
3 approved / phase 46 Phase 31 Phase 21 Phase 1/2
Head-to-head evidence: BCD-248 vs Elranatamab · BCD-248 vs GR1803 · BCD-248 vs REGN5459 · BCD-248 vs Teclistamab · CM336 vs Elranatamab · CM336 vs GR1803